Author:
Alcaide Miguel,Cheung Matthew,Hillman Jack,Rassekh S. Rod,Deyell Rebecca J.,Batist Gerald,Karsan Aly,Wyatt Alexander W.,Johnson Nathalie,Scott David W.,Morin Ryan D.
Abstract
AbstractCell-free DNA (cfDNA) has become a comprehensive biomarker in the fields of non-invasive cancer detection and monitoring, organ transplantation, prenatal genetic testing and pathogen detection. While cfDNA samples can be obtained using a broad variety of approaches, there is an urgent need to standardize analytical tools aimed at assessing its basic properties. Typical methods to determine the yield and fragment size distribution of cfDNA samples are usually either blind to genomic DNA contamination or the presence of enzymatic inhibitors, which can confound and undermine downstream analyses. Here, we present a novel droplet digital PCR assay to identify suboptimal samples and aberrant cfDNA size distributions, the latter typically associated with high levels of circulating tumour DNA (ctDNA). Our assay was designed to promiscuously cross-amplify members of the human olfactory receptor (OR) gene family and includes a customizable diploid locus for the determination of absolute cfDNA concentrations. We demonstrate here the utility of our assay to estimate the yield and quality of cfDNA extracts and deduce fragment size distributions that correlate well with those inferred by capillary electrophoresis and high throughput sequencing. The assay described herein is a powerful tool to establish quality controls and stratify cfDNA samples based on presumed ctDNA levels, then facilitating the implementation of robust, cost-effective and standardized analytical workflows into clinical practice.
Funder
Canadian Institutes for Health Research
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Mandel, P. Les acides nucleiques du plasma sanguin chez 1 homme. C R Seances Soc. Biol. Fil 142, 241–243 (1948).
2. Norwitz, E. R. & Levy, B. Noninvasive prenatal testing: the future is now. Rev. Obstet. Gynecol. 6, 48–62 (2013).
3. Volik, S., Alcaide, M., Morin, R. D. & Collins, C. C. Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Mol. Cancer Res. https://doi.org/10.1158/1541-7786.MCR-16-0044 (2016).
4. Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223–238 (2017).
5. Knight, S. R., Thorne, A. & Lo Faro, M. L. Donor-specific cell-free DNA as a biomarker in solid organ transplantation. A systematic review. Transplantation 103, 273–283 (2019).
Cited by
79 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献